IMAGE SOURCE: GETTY IMAGES.
Continue Reading Below
After the company released its third-quarter financials, launched Rayaldee, and updated investors on its clinical-drug pipeline, shares in Opko Health (NASDAQ: OPK) climbed 9% in November, according to S&P Global Market Intelligence.
Opko Health's legendary CEO Phillip Frost is beginning to reap the benefit of a multiyear string of mergers and acquisitions designed to position the company as a diversified healthcare leader.
In the third quarter, ongoing demand for specialty lab services at its Bio-Reference Laboratories, which Frost acquired in 2015, resulted in consolidated revenue of $298 million and a net loss of $15 million. Opko Health finished the quarter with $145 million in cash.
The company also reported on Nov. 23 that Rayaldee, a vitamin D prohormone, would become commercially available on Nov. 30. The launch of Rayaldee could prove significant, given that it could become a standard of care used to treat vitamin D deficiency in millions of patients with chronic kidney disease.
Opko Health also told industry-watchers that it remains on track to deliver data for its long-acting human growth hormone, hGH-CTP, before the end of this year. The drug is licensed to Pfizer; if it's successful, it could end up competing in a market valued in the hundreds of millions of dollars annually.
Bio-Reference Labs is a big driver of revenue, but Rayaldee could begin contributing sales next year, and success for hGH-CTP could lead to milestone revenue and an FDA application for approval in 2017.
The size of Rayaldee's addressable market, and the historical sales figures for other drugs such as Hectorol used in the same indication, suggest that Rayaldee could have nine-figure sales potential.
Opko Health could also receive up to $275.0 million in regulatory milestone payments from Pfizer, and royalty rates ranging from the high teens to mid-twenties. If hGH-CTP is eventually launched for use in children, then those royalties will transition to profit-sharing on hGH-CTP and Pfizer's Genotropin, a commonly prescribed human growth hormone with Q3 2015 sales of $147 million.
Given all the needle-moving developments at Opko Health, it's not surprising that investors are starting to get a bit more enthusiastic. However, investors should remember that there's no guarantee of Rayaldee's commercial success, nor of success in hGH-CTP's trials. For these reasons, some caution is warranted.
10 stocks we like better than Opko Health When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Opko Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of Nov. 7, 2016
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him onTwitter where he goes by the handle@ebcapitalto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.